ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Oncolytic Virus Cancer Immunotherapy Market Insights, Forecast to 2030
Published Date: December 2024
|
Report Code: QYRE-Auto-16V16446
Home | Market Reports | Health| Health Conditions| Cancer
Global Oncolytic Virus Cancer Immunotherapy Market Research Report 2024
BUY CHAPTERS

Global Oncolytic Virus Cancer Immunotherapy Market Insights, Forecast to 2030

Code: QYRE-Auto-16V16446
Report
December 2024
Pages:112
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Astrazeneca plc
Amgen Inc
F. Hoffman-La Roche
Bristol–Myers Squibb
Novartis
Merck& Co. Inc
Pfizer Inc
BioVex
Cell Genesys
Crusade Laboratories
Genelux Corporation
Lokon Pharma
MultiVir

Oncolytic Virus Cancer Immunotherapy Market

Oncolytic virus is a special virus that can beneficially infect and kill cancer cells. These are deployed as part of cancer immunotherapy and work by selectively targeting cancer cells and performing oncolytics. Oncolytic viruses can not only kill cancer cells directly, but also stimulate patients' own anti-tumor immune response.
Market Analysis and Insights: Global Oncolytic Virus Cancer Immunotherapy Market
The global Oncolytic Virus Cancer Immunotherapy market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The first oncolytic virus immunotherapy was approved in Latvia in 2004 for the treatment of cutaneous melanoma. Inevitable changes in the environment due to human activities are causing various factors, leading to an increase in the incidence of many skin malignancies, including non-melanoma skin cancer. Conventional radiation and chemotherapy known to treat various cancers, including cutaneous melanoma, have a limited therapeutic index and a range of treatment-related side effects.
Report Covers:
This report presents an overview of global market for Oncolytic Virus Cancer Immunotherapy market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Oncolytic Virus Cancer Immunotherapy, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Oncolytic Virus Cancer Immunotherapy, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Oncolytic Virus Cancer Immunotherapy revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Oncolytic Virus Cancer Immunotherapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Oncolytic Virus Cancer Immunotherapy revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation

Scope of Oncolytic Virus Cancer Immunotherapy Market Report

Report Metric Details
Report Name Oncolytic Virus Cancer Immunotherapy Market
Segment by Type
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company AstraZeneca, Amgen, F Hoffman-La Roche, Bristol-Myers Squibb, Novartis AG, Merck & Co., Inc., Pfizer, Biovex, Cell Genesys, Crusade Laboratories, Genelux Corporation, Lokon Pharma, MultiVir
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Revenue of Oncolytic Virus Cancer Immunotherapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Oncolytic Virus Cancer Immunotherapy companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
  • Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
  • Chapter 8: China by Type, and by Application, revenue for each segment.
  • Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
  • Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
  • Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oncolytic Virus Cancer Immunotherapy revenue, gross margin, and recent development, etc.
  • Chapter 12: Analyst's Viewpoints/Conclusions

FAQ for this report

Who are the main players in the Oncolytic Virus Cancer Immunotherapy Market report?

Ans: The main players in the Oncolytic Virus Cancer Immunotherapy Market are AstraZeneca, Amgen, F Hoffman-La Roche, Bristol-Myers Squibb, Novartis AG, Merck & Co., Inc., Pfizer, Biovex, Cell Genesys, Crusade Laboratories, Genelux Corporation, Lokon Pharma, MultiVir

What are the Application segmentation covered in the Oncolytic Virus Cancer Immunotherapy Market report?

Ans: The Applications covered in the Oncolytic Virus Cancer Immunotherapy Market report are Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head and neck Cancer, Ovarian Cancer, Pancreatic Cancer, Others

What are the Type segmentation covered in the Oncolytic Virus Cancer Immunotherapy Market report?

Ans: The Types covered in the Oncolytic Virus Cancer Immunotherapy Market report are Monoclonal Antibodies, Checkpoint Inhibitors, Oncoloytic Viral Therapies and Cancer Vaccines

Recommended Reports

Cancer Immunotherapy

Tumor Gene Therapies

Cancer Treatment Therapeutics

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Monoclonal Antibodies
1.2.3 Checkpoint Inhibitors
1.2.4 Oncoloytic Viral Therapies and Cancer Vaccines
1.3 Market by Application
1.3.1 Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Lung Cancer
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Melanoma
1.3.6 Prostate Cancer
1.3.7 Head and neck Cancer
1.3.8 Ovarian Cancer
1.3.9 Pancreatic Cancer
1.3.10 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oncolytic Virus Cancer Immunotherapy Market Perspective (2019-2030)
2.2 Global Oncolytic Virus Cancer Immunotherapy Growth Trends by Region
2.2.1 Oncolytic Virus Cancer Immunotherapy Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Oncolytic Virus Cancer Immunotherapy Historic Market Size by Region (2019-2024)
2.2.3 Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Region (2025-2030)
2.3 Oncolytic Virus Cancer Immunotherapy Market Dynamics
2.3.1 Oncolytic Virus Cancer Immunotherapy Industry Trends
2.3.2 Oncolytic Virus Cancer Immunotherapy Market Drivers
2.3.3 Oncolytic Virus Cancer Immunotherapy Market Challenges
2.3.4 Oncolytic Virus Cancer Immunotherapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Oncolytic Virus Cancer Immunotherapy by Players
3.1.1 Global Oncolytic Virus Cancer Immunotherapy Revenue by Players (2019-2024)
3.1.2 Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Players (2019-2024)
3.2 Global Oncolytic Virus Cancer Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Oncolytic Virus Cancer Immunotherapy, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio
3.4.1 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncolytic Virus Cancer Immunotherapy Revenue in 2023
3.5 Global Key Players of Oncolytic Virus Cancer Immunotherapy Head office and Area Served
3.6 Global Key Players of Oncolytic Virus Cancer Immunotherapy, Product and Application
3.7 Global Key Players of Oncolytic Virus Cancer Immunotherapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Oncolytic Virus Cancer Immunotherapy Breakdown Data by Type
4.1 Global Oncolytic Virus Cancer Immunotherapy Historic Market Size by Type (2019-2024)
4.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Type (2025-2030)
5 Oncolytic Virus Cancer Immunotherapy Breakdown Data by Application
5.1 Global Oncolytic Virus Cancer Immunotherapy Historic Market Size by Application (2019-2024)
5.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Oncolytic Virus Cancer Immunotherapy Market Size (2019-2030)
6.2 North America Oncolytic Virus Cancer Immunotherapy Market Size by Type
6.2.1 North America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2019-2024)
6.2.2 North America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2025-2030)
6.2.3 North America Oncolytic Virus Cancer Immunotherapy Market Share by Type (2019-2030)
6.3 North America Oncolytic Virus Cancer Immunotherapy Market Size by Application
6.3.1 North America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2019-2024)
6.3.2 North America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2025-2030)
6.3.3 North America Oncolytic Virus Cancer Immunotherapy Market Share by Application (2019-2030)
6.4 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country
6.4.1 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2019-2024)
6.4.3 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size (2019-2030)
7.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type
7.2.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type (2019-2024)
7.2.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type (2025-2030)
7.2.3 Europe Oncolytic Virus Cancer Immunotherapy Market Share by Type (2019-2030)
7.3 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application
7.3.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application (2019-2024)
7.3.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application (2025-2030)
7.3.3 Europe Oncolytic Virus Cancer Immunotherapy Market Share by Application (2019-2030)
7.4 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country
7.4.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2019-2024)
7.4.3 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Oncolytic Virus Cancer Immunotherapy Market Size (2019-2030)
8.2 China Oncolytic Virus Cancer Immunotherapy Market Size by Type
8.2.1 China Oncolytic Virus Cancer Immunotherapy Market Size by Type (2019-2024)
8.2.2 China Oncolytic Virus Cancer Immunotherapy Market Size by Type (2025-2030)
8.2.3 China Oncolytic Virus Cancer Immunotherapy Market Share by Type (2019-2030)
8.3 China Oncolytic Virus Cancer Immunotherapy Market Size by Application
8.3.1 China Oncolytic Virus Cancer Immunotherapy Market Size by Application (2019-2024)
8.3.2 China Oncolytic Virus Cancer Immunotherapy Market Size by Application (2025-2030)
8.3.3 China Oncolytic Virus Cancer Immunotherapy Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Oncolytic Virus Cancer Immunotherapy Market Size (2019-2030)
9.2 Asia Oncolytic Virus Cancer Immunotherapy Market Size by Type
9.2.1 Asia Oncolytic Virus Cancer Immunotherapy Market Size by Type (2019-2024)
9.2.2 Asia Oncolytic Virus Cancer Immunotherapy Market Size by Type (2025-2030)
9.2.3 Asia Oncolytic Virus Cancer Immunotherapy Market Share by Type (2019-2030)
9.3 Asia Oncolytic Virus Cancer Immunotherapy Market Size by Application
9.3.1 Asia Oncolytic Virus Cancer Immunotherapy Market Size by Application (2019-2024)
9.3.2 Asia Oncolytic Virus Cancer Immunotherapy Market Size by Application (2025-2030)
9.3.3 Asia Oncolytic Virus Cancer Immunotherapy Market Share by Application (2019-2030)
9.4 Asia Oncolytic Virus Cancer Immunotherapy Market Size by Region
9.4.1 Asia Oncolytic Virus Cancer Immunotherapy Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Oncolytic Virus Cancer Immunotherapy Market Size by Region (2019-2024)
9.4.3 Asia Oncolytic Virus Cancer Immunotherapy Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Oncolytic Virus Cancer Immunotherapy Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type
10.2.1 Middle East, Africa, and Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Oncolytic Virus Cancer Immunotherapy Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application
10.3.1 Middle East, Africa, and Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Oncolytic Virus Cancer Immunotherapy Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country
10.4.1 Middle East, Africa, and Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Oncolytic Virus Cancer Immunotherapy Introduction
11.1.4 AstraZeneca Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.1.5 AstraZeneca Recent Developments
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Oncolytic Virus Cancer Immunotherapy Introduction
11.2.4 Amgen Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.2.5 Amgen Recent Developments
11.3 F Hoffman-La Roche
11.3.1 F Hoffman-La Roche Company Details
11.3.2 F Hoffman-La Roche Business Overview
11.3.3 F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Introduction
11.3.4 F Hoffman-La Roche Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.3.5 F Hoffman-La Roche Recent Developments
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Introduction
11.4.4 Bristol-Myers Squibb Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.4.5 Bristol-Myers Squibb Recent Developments
11.5 Novartis AG
11.5.1 Novartis AG Company Details
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Oncolytic Virus Cancer Immunotherapy Introduction
11.5.4 Novartis AG Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.5.5 Novartis AG Recent Developments
11.6 Merck & Co., Inc.
11.6.1 Merck & Co., Inc. Company Details
11.6.2 Merck & Co., Inc. Business Overview
11.6.3 Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Introduction
11.6.4 Merck & Co., Inc. Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.6.5 Merck & Co., Inc. Recent Developments
11.7 Pfizer
11.7.1 Pfizer Company Details
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Oncolytic Virus Cancer Immunotherapy Introduction
11.7.4 Pfizer Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.7.5 Pfizer Recent Developments
11.8 Biovex
11.8.1 Biovex Company Details
11.8.2 Biovex Business Overview
11.8.3 Biovex Oncolytic Virus Cancer Immunotherapy Introduction
11.8.4 Biovex Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.8.5 Biovex Recent Developments
11.9 Cell Genesys
11.9.1 Cell Genesys Company Details
11.9.2 Cell Genesys Business Overview
11.9.3 Cell Genesys Oncolytic Virus Cancer Immunotherapy Introduction
11.9.4 Cell Genesys Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.9.5 Cell Genesys Recent Developments
11.10 Crusade Laboratories
11.10.1 Crusade Laboratories Company Details
11.10.2 Crusade Laboratories Business Overview
11.10.3 Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Introduction
11.10.4 Crusade Laboratories Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.10.5 Crusade Laboratories Recent Developments
11.11 Genelux Corporation
11.11.1 Genelux Corporation Company Details
11.11.2 Genelux Corporation Business Overview
11.11.3 Genelux Corporation Oncolytic Virus Cancer Immunotherapy Introduction
11.11.4 Genelux Corporation Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.11.5 Genelux Corporation Recent Developments
11.12 Lokon Pharma
11.12.1 Lokon Pharma Company Details
11.12.2 Lokon Pharma Business Overview
11.12.3 Lokon Pharma Oncolytic Virus Cancer Immunotherapy Introduction
11.12.4 Lokon Pharma Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.12.5 Lokon Pharma Recent Developments
11.13 MultiVir
11.13.1 MultiVir Company Details
11.13.2 MultiVir Business Overview
11.13.3 MultiVir Oncolytic Virus Cancer Immunotherapy Introduction
11.13.4 MultiVir Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
11.13.5 MultiVir Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
FEATURED COMPANIES
Astrazeneca plc
Amgen Inc
F. Hoffman-La Roche
Bristol–Myers Squibb
Novartis
Merck& Co. Inc
Pfizer Inc
BioVex
Cell Genesys
Crusade Laboratories
Genelux Corporation
Lokon Pharma
MultiVir
List of Tables
    Table 1. Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Monoclonal Antibodies
    Table 3. Key Players of Checkpoint Inhibitors
    Table 4. Key Players of Oncoloytic Viral Therapies and Cancer Vaccines
    Table 5. Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 6. Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 7. Global Oncolytic Virus Cancer Immunotherapy Market Size by Region (2019-2024) & (US$ Million)
    Table 8. Global Oncolytic Virus Cancer Immunotherapy Market Share by Region (2019-2024)
    Table 9. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 10. Global Oncolytic Virus Cancer Immunotherapy Market Share by Region (2025-2030)
    Table 11. Oncolytic Virus Cancer Immunotherapy Market Trends
    Table 12. Oncolytic Virus Cancer Immunotherapy Market Drivers
    Table 13. Oncolytic Virus Cancer Immunotherapy Market Challenges
    Table 14. Oncolytic Virus Cancer Immunotherapy Market Restraints
    Table 15. Global Oncolytic Virus Cancer Immunotherapy Revenue by Players (2019-2024) & (US$ Million)
    Table 16. Global Oncolytic Virus Cancer Immunotherapy Revenue Share by Players (2019-2024)
    Table 17. Global Top Oncolytic Virus Cancer Immunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Cancer Immunotherapy as of 2023)
    Table 18. Global Oncolytic Virus Cancer Immunotherapy Industry Ranking 2022 VS 2023 VS 2024
    Table 19. Global 5 Largest Players Market Share by Oncolytic Virus Cancer Immunotherapy Revenue (CR5 and HHI) & (2019-2024)
    Table 20. Global Key Players of Oncolytic Virus Cancer Immunotherapy, Headquarters and Area Served
    Table 21. Global Key Players of Oncolytic Virus Cancer Immunotherapy, Product and Application
    Table 22. Global Key Players of Oncolytic Virus Cancer Immunotherapy, Product and Application
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Oncolytic Virus Cancer Immunotherapy Market Size by Type (2019-2024) & (US$ Million)
    Table 25. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Type (2019-2024)
    Table 26. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 27. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Type (2025-2030)
    Table 28. Global Oncolytic Virus Cancer Immunotherapy Market Size by Application (2019-2024) & (US$ Million)
    Table 29. Global Oncolytic Virus Cancer Immunotherapy Revenue Share by Application (2019-2024)
    Table 30. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 31. Global Oncolytic Virus Cancer Immunotherapy Revenue Share by Application (2025-2030)
    Table 32. North America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2019-2024) & (US$ Million)
    Table 33. North America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2025-2030) & (US$ Million)
    Table 34. North America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2019-2024) & (US$ Million)
    Table 35. North America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2025-2030) & (US$ Million)
    Table 36. North America Oncolytic Virus Cancer Immunotherapy Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 37. North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2019-2024) & (US$ Million)
    Table 38. North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2025-2030) & (US$ Million)
    Table 39. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type (2019-2024) & (US$ Million)
    Table 40. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type (2025-2030) & (US$ Million)
    Table 41. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application (2019-2024) & (US$ Million)
    Table 42. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application (2025-2030) & (US$ Million)
    Table 43. Europe Oncolytic Virus Cancer Immunotherapy Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 44. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2019-2024) & (US$ Million)
    Table 45. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2025-2030) & (US$ Million)
    Table 46. China Oncolytic Virus Cancer Immunotherapy Market Size by Type (2019-2024) & (US$ Million)
    Table 47. China Oncolytic Virus Cancer Immunotherapy Market Size by Type (2025-2030) & (US$ Million)
    Table 48. China Oncolytic Virus Cancer Immunotherapy Market Size by Application (2019-2024) & (US$ Million)
    Table 49. China Oncolytic Virus Cancer Immunotherapy Market Size by Application (2025-2030) & (US$ Million)
    Table 50. Asia Oncolytic Virus Cancer Immunotherapy Market Size by Type (2019-2024) & (US$ Million)
    Table 51. Asia Oncolytic Virus Cancer Immunotherapy Market Size by Type (2025-2030) & (US$ Million)
    Table 52. Asia Oncolytic Virus Cancer Immunotherapy Market Size by Application (2019-2024) & (US$ Million)
    Table 53. Asia Oncolytic Virus Cancer Immunotherapy Market Size by Application (2025-2030) & (US$ Million)
    Table 54. Asia Oncolytic Virus Cancer Immunotherapy Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 55. Asia Oncolytic Virus Cancer Immunotherapy Market Size by Region (2019-2024) & (US$ Million)
    Table 56. Asia Oncolytic Virus Cancer Immunotherapy Market Size by Region (2025-2030) & (US$ Million)
    Table 57. Middle East, Africa, and Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2019-2024) & (US$ Million)
    Table 58. Middle East, Africa, and Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2025-2030) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2019-2024) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2025-2030) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America Oncolytic Virus Cancer Immunotherapy Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 62. Middle East, Africa, and Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2019-2024) & (US$ Million)
    Table 63. Middle East, Africa, and Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2025-2030) & (US$ Million)
    Table 64. AstraZeneca Company Details
    Table 65. AstraZeneca Business Overview
    Table 66. AstraZeneca Oncolytic Virus Cancer Immunotherapy Product
    Table 67. AstraZeneca Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)
    Table 68. AstraZeneca Recent Developments
    Table 69. Amgen Company Details
    Table 70. Amgen Business Overview
    Table 71. Amgen Oncolytic Virus Cancer Immunotherapy Product
    Table 72. Amgen Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)
    Table 73. Amgen Recent Developments
    Table 74. F Hoffman-La Roche Company Details
    Table 75. F Hoffman-La Roche Business Overview
    Table 76. F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Product
    Table 77. F Hoffman-La Roche Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)
    Table 78. F Hoffman-La Roche Recent Developments
    Table 79. Bristol-Myers Squibb Company Details
    Table 80. Bristol-Myers Squibb Business Overview
    Table 81. Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Product
    Table 82. Bristol-Myers Squibb Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)
    Table 83. Bristol-Myers Squibb Recent Developments
    Table 84. Novartis AG Company Details
    Table 85. Novartis AG Business Overview
    Table 86. Novartis AG Oncolytic Virus Cancer Immunotherapy Product
    Table 87. Novartis AG Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)
    Table 88. Novartis AG Recent Developments
    Table 89. Merck & Co., Inc. Company Details
    Table 90. Merck & Co., Inc. Business Overview
    Table 91. Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Product
    Table 92. Merck & Co., Inc. Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)
    Table 93. Merck & Co., Inc. Recent Developments
    Table 94. Pfizer Company Details
    Table 95. Pfizer Business Overview
    Table 96. Pfizer Oncolytic Virus Cancer Immunotherapy Product
    Table 97. Pfizer Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)
    Table 98. Pfizer Recent Developments
    Table 99. Biovex Company Details
    Table 100. Biovex Business Overview
    Table 101. Biovex Oncolytic Virus Cancer Immunotherapy Product
    Table 102. Biovex Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)
    Table 103. Biovex Recent Developments
    Table 104. Cell Genesys Company Details
    Table 105. Cell Genesys Business Overview
    Table 106. Cell Genesys Oncolytic Virus Cancer Immunotherapy Product
    Table 107. Cell Genesys Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)
    Table 108. Cell Genesys Recent Developments
    Table 109. Crusade Laboratories Company Details
    Table 110. Crusade Laboratories Business Overview
    Table 111. Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Product
    Table 112. Crusade Laboratories Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)
    Table 113. Crusade Laboratories Recent Developments
    Table 114. Genelux Corporation Company Details
    Table 115. Genelux Corporation Business Overview
    Table 116. Genelux Corporation Oncolytic Virus Cancer Immunotherapy Product
    Table 117. Genelux Corporation Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)
    Table 118. Genelux Corporation Recent Developments
    Table 119. Lokon Pharma Company Details
    Table 120. Lokon Pharma Business Overview
    Table 121. Lokon Pharma Oncolytic Virus Cancer Immunotherapy Product
    Table 122. Lokon Pharma Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)
    Table 123. Lokon Pharma Recent Developments
    Table 124. MultiVir Company Details
    Table 125. MultiVir Business Overview
    Table 126. MultiVir Oncolytic Virus Cancer Immunotherapy Product
    Table 127. MultiVir Revenue in Oncolytic Virus Cancer Immunotherapy Business (2019-2024) & (US$ Million)
    Table 128. MultiVir Recent Developments
    Table 129. Research Programs/Design for This Report
    Table 130. Key Data Information from Secondary Sources
    Table 131. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Oncolytic Virus Cancer Immunotherapy Market Share by Type: 2023 VS 2030
    Figure 3. Monoclonal Antibodies Features
    Figure 4. Checkpoint Inhibitors Features
    Figure 5. Oncoloytic Viral Therapies and Cancer Vaccines Features
    Figure 6. Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 7. Global Oncolytic Virus Cancer Immunotherapy Market Share by Application: 2023 VS 2030
    Figure 8. Lung Cancer Case Studies
    Figure 9. Breast Cancer Case Studies
    Figure 10. Colorectal Cancer Case Studies
    Figure 11. Melanoma Case Studies
    Figure 12. Prostate Cancer Case Studies
    Figure 13. Head and neck Cancer Case Studies
    Figure 14. Ovarian Cancer Case Studies
    Figure 15. Pancreatic Cancer Case Studies
    Figure 16. Others Case Studies
    Figure 17. Oncolytic Virus Cancer Immunotherapy Report Years Considered
    Figure 18. Global Oncolytic Virus Cancer Immunotherapy Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 19. Global Oncolytic Virus Cancer Immunotherapy Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 20. Global Oncolytic Virus Cancer Immunotherapy Market Share by Region: 2023 VS 2030
    Figure 21. Global Oncolytic Virus Cancer Immunotherapy Market Share by Players in 2023
    Figure 22. Global Top Oncolytic Virus Cancer Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Cancer Immunotherapy as of 2023)
    Figure 23. The Top 10 and 5 Players Market Share by Oncolytic Virus Cancer Immunotherapy Revenue in 2023
    Figure 24. North America Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 25. North America Oncolytic Virus Cancer Immunotherapy Market Share by Type (2019-2030)
    Figure 26. North America Oncolytic Virus Cancer Immunotherapy Market Share by Application (2019-2030)
    Figure 27. North America Oncolytic Virus Cancer Immunotherapy Market Share by Country (2019-2030)
    Figure 28. United States Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. Canada Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. Europe Oncolytic Virus Cancer Immunotherapy Market Size YoY (2019-2030) & (US$ Million)
    Figure 31. Europe Oncolytic Virus Cancer Immunotherapy Market Share by Type (2019-2030)
    Figure 32. Europe Oncolytic Virus Cancer Immunotherapy Market Share by Application (2019-2030)
    Figure 33. Europe Oncolytic Virus Cancer Immunotherapy Market Share by Country (2019-2030)
    Figure 34. Germany Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. France Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. U.K. Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 37. Italy Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 38. Russia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 39. Nordic Countries Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 40. China Oncolytic Virus Cancer Immunotherapy Market Size YoY (2019-2030) & (US$ Million)
    Figure 41. China Oncolytic Virus Cancer Immunotherapy Market Share by Type (2019-2030)
    Figure 42. China Oncolytic Virus Cancer Immunotherapy Market Share by Application (2019-2030)
    Figure 43. Asia Oncolytic Virus Cancer Immunotherapy Market Size YoY (2019-2030) & (US$ Million)
    Figure 44. Asia Oncolytic Virus Cancer Immunotherapy Market Share by Type (2019-2030)
    Figure 45. Asia Oncolytic Virus Cancer Immunotherapy Market Share by Application (2019-2030)
    Figure 46. Asia Oncolytic Virus Cancer Immunotherapy Market Share by Region (2019-2030)
    Figure 47. Japan Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 48. South Korea Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 49. China Taiwan Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 50. Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 51. India Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 52. Australia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 53. Middle East, Africa, and Latin America Oncolytic Virus Cancer Immunotherapy Market Size YoY (2019-2030) & (US$ Million)
    Figure 54. Middle East, Africa, and Latin America Oncolytic Virus Cancer Immunotherapy Market Share by Type (2019-2030)
    Figure 55. Middle East, Africa, and Latin America Oncolytic Virus Cancer Immunotherapy Market Share by Application (2019-2030)
    Figure 56. Middle East, Africa, and Latin America Oncolytic Virus Cancer Immunotherapy Market Share by Country (2019-2030)
    Figure 57. Brazil Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 58. Mexico Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 59. Turkey Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 60. Saudi Arabia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 61. Israel Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 62. GCC Countries Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 63. AstraZeneca Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
    Figure 64. Amgen Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
    Figure 65. F Hoffman-La Roche Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
    Figure 66. Bristol-Myers Squibb Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
    Figure 67. Novartis AG Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
    Figure 68. Merck & Co., Inc. Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
    Figure 69. Pfizer Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
    Figure 70. Biovex Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
    Figure 71. Cell Genesys Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
    Figure 72. Crusade Laboratories Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
    Figure 73. Genelux Corporation Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
    Figure 74. Lokon Pharma Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
    Figure 75. MultiVir Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2019-2024)
    Figure 76. Bottom-up and Top-down Approaches for This Report
    Figure 77. Data Triangulation
    Figure 78. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

Global Oncolytic Virus Market Insights Forecast to 2030
Global Oncolytic Virus Immunotherapy Market Research Report 2024
Global Oncolytic Virus Manufacturing and Development Services Market Research Report 2024
Global Oncolytic Viral Drugs Market Research Report 2024
Global Oncolytic Virus Manufacturing Services Market Research Report 2024
Global Immuno oncology Therapy Market Insights Forecast to 2030
Global Cancer Immunotherapy Drugs Market Research Report 2024
Global Cancer Immunosuppressant Treatment Market Research Report 2024
Global Gene Therapies for Tumor Treatment Market Insights Forecast to 2030
Global Cancer Immuno Personalized Medicine Market Research Report 2024
Global Immunotherapy Drugs Market Research Report 2024
Global Immunosuppressants in Cancer Therapy Market Research Report 2024
Immuno oncology Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Immunotherapeutic Drugs Market Insights Forecast to 2030
Global Immuno Cell Therapy Market Research Report 2024
Global Oncolytic Virus Therapy Market Research Report 2025
Global Cancer Immunotherapy Market Insights Forecast to 2030
Cancer Immunotherapy Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Immuno Oncology Service Market Research Report 2024
Global Cancer Immunotherapies Market Insights Forecast to 2030

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-5L19798
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-28I6901
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22R9736
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-29A2598
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions